Castle Biosciences is a commercial-stage dermatological diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Co.'s main product, DecisionDx-Melanoma, is a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis or recurrence for patients diagnosed with invasive cutaneous melanoma, a deadly skin cancer. Co. has commercially launched its cutaneous squamous cell carcinoma (SCC) proprietary GEP test, DecisionDx®-SCC, for use in patients with one or more risk factors. We show 18 historical shares outstanding datapoints in our CSTL shares outstanding history coverage, used to compute CSTL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CSTL market cap history over the course of time is important for investors
interested in comparing CSTL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CSTL versus a peer is one thing; comparing
CSTL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CSTL can fluctuate over the course of history.
With this page we aim to empower investors researching CSTL by allowing them to research the CSTL market cap history. |
Free CSTL Email Alerts:
Video: The Importance of Market Cap
